REMARKS

Claims 40, 45 and 48-49 are now pending.

On page 2 of the Office Action, the Examiner rejects Claim 40 under 35 U.S.C. § 102(b) as being anticipated by Gjertsen et al.

Specifically, it is the Examiner's position that Gjertsen et al teaches a composition comprising Rp-8-4-chlorophenyl-thio-cAMPs and a buffer. The Examiner contends that the buffer would be encompassed by the term "a pharmaceutically acceptable adjuvant or filler" as recited in Claim 40.

While Applicants respectfully disagree with the Examiner's rejection for the reasons of record, in order to advance prosecution, Applicants hereby delete Rp-8-(4-chlorophenylthio)-cAMPs from Claim 40, thereby rendering moot the Examiner's rejection as to Claim 40.

Accordingly, Applicants respectfully submit that the present invention is not taught or suggested in Gjersten et al, and thus request withdrawal of the Examiner's rejection.

On page 3 of the Office Action, the Examiner rejects Claims 40, 45 and 48 under 35 U.S.C. § 102 as being anticipated by Jackson (newly cited).

Specifically the Examiner states that Jackson discloses a pharmaceutical composition comprising Rp-8-4-chlorophenyl-thio-cAMPs, and administering the composition to a subject. It is the Examiner's contention that administering the composition to a subject would inherently enhance T-cell proliferation, and that the hamster of Jackson is considered to be in need thereof because enhanced T-cell proliferation is beneficial to the immune system, for example, in avoiding infection.

For the following reasons, Applicants respectfully traverse the Examiner's rejection.

Initially, as noted above, Rp-8-(4-chlorophenylthio)-cAMPs has been deleted from Claim 40, thereby rendering moot the Examiner's rejection as to Claim 40.

As to Claims 45 and 48, Jackson et al does not teach or suggest administering a pharmaceutical composition comprising Rp-8-(4-chlorophenylthio)-cAMPS to a hamster. Specifically, Jackson et al (page 228), under the heading "Solution and Drugs", teaches that the drugs were made as concentrated stock solutions and diluted in PSS and stored on ice until used. The drugs were then added to a bath, and not administered to animals. The bath contained mesenteric arterial segments which had been dissected out of hamsters (see page 227, right-hand column, under the heading "Animals and Vessel Preparation", and page 228 under the heading "Experimental Protocols"). Moreover, the first step described in the "Animals and Vessel preparation" section is the step of anaesthetizing the hamsters using pentobarbital sodium at amounts that would kill the animals, and then dissection of their ileum. Thus, Jackson et al does not disclose administration of any drug to hamsters. Since there is no administration of any of the drugs to a hamster in Jackson et al, there can be no inherent enhancement of T-cell proliferation therein. Further, the segments were first washed before placing in the bath. As a result, Jackson et al does not have anything to do with T cells. As such, Jackson et al does not disclose a method for enhancing T-cell proliferation as recited in Claims 45 and 48.

Accordingly, Applicants respectfully submit that the present invention is not taught or suggested in Jackson, and thus request withdrawal of the Examiner's rejection.

Applicants note, as indicated at page 4 of the Office Action, Claim 49 is objected to, but would be allowable if rewritten as an independent claim.

In view of the amendments to the claims, the Examiner is requested to pass the case to issuance.

The Examiner is invited to contact the undersigned at his Washington telephone number on any questions which might arise.

Respectfully submitted,



Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: April 4, 2005